News Gilead, Arcus say TIGIT combo encouraging in GI cancer Gilead and Arcus’ efforts to rebuild confidence in TIGIT as a drug target for cancer immunotherapies have shuffled forwards again, with new data showing signs of efficacy
Events Partner Content FREE - Gastrointestinal Cancer Drug Development Digital Summ... FREE - Gastrointestinal Cancer Drug Development Summit
News Ipsen charts $1.75bn course for Kartos acquisition Ipsen has agreed to buy cancer biotech Kartos Therapeutics for $450m upfront, adding a late-stage drug in the challenging MDM2 inhibitor class.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
